| Page 11 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy

Author(s): 
Iftikhar R, DeFilipp Z, DeZern AE, Pulsipher MA, Bejanyan N, Burroughs LM, Kharfan-Dabaja MA, Arai S, Kassim A, Nakamura R, Saldaña BJD, Aljurf M, Hamadani M, Carpenter PA, Antin JH.
Primary Author: 
Iftikhar R
Journal Title: 
Transplantation and Cellular Therapy
Original Publication Date: 
Sep 2024

Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for severe

Bone Marrow Disease(s): 

Real-World Study of the Burden of Myelodysplastic Syndromes in Patients and Their Caregivers in Europe and the United States

Author(s): 
Lewis K, Williamson M, Brown E, Trenholm E, Hogea C
Primary Author: 
Lewis K
Journal Title: 
Oncology and Therapy
Original Publication Date: 
Dec 2024

Introduction: 

Bone Marrow Disease(s): 

Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes

Author(s): 
Garcia JS, Platzbecker U, Odenike O, Fleming SA, Fong CY, Borate U, Jacoby MA, Nowak D, Baer MR, Peterlin P, Chyla B, Wang H, Ku G, Hoffman D, Potluri J, Garcia-Manero G
Primary Author: 
Garcia JS
Journal Title: 
Blood
Original Publication Date: 
Dec 2024

Patients with higher-risk

Bone Marrow Disease(s):